🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Lee Ainslie’s CRL Holdings & Trades

First Buy
Q3 2020
Duration Held
6 Quarters
Largest Add
Q1 2026
+8,178 Shares
Current Position
8,178 Shares
$1.41 M Value

Lee Ainslie's CRL Position Overview

Lee Ainslie (via Maverick Capital LTD) currently holds 8,178 shares of Charles River Laboratories International, Inc. (CRL) worth $1.41 M, representing 0.02% of the portfolio. First purchased in 2020-Q3, this short-term holding has been held for 6 quarters.

Based on 13F filings, Lee Ainslie has maintained this position in CRL for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 8,178 shares. Largest reduction occurred in Q2 2021, reducing 3,363 shares.

Analysis based on 13F filings available since 2013 Q2

Lee Ainslie's Charles River Laboratories International (CRL) Holding Value Over Time

Track share changes against reported price movement

Quarterly Charles River Laboratories International (CRL) Trades by Lee Ainslie

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +8,178 New Buy 8,178 $172.50
Q3 2021 -1,536 Sold Out 0 $0.00
Q2 2021 -3,363 Reduce 68.65% 1,536 $369.79
Q1 2021 +4,899 New Buy 4,899 $289.86
Q4 2020 -1,162 Sold Out 0 $0.00
Q3 2020 +1,162 New Buy 1,162 $226.33

Lee Ainslie's Charles River Laboratories International Investment FAQs

Lee Ainslie first purchased Charles River Laboratories International, Inc. (CRL) in Q3 2020, acquiring 1,162 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Lee Ainslie has held Charles River Laboratories International, Inc. (CRL) for 6 quarters since Q3 2020.

Lee Ainslie's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q1 2026, adding 8,178 shares worth $1.41 M.

According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 8,178 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $1.41 M.

As of the Q1 2026 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.02% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.

Lee Ainslie's peak holding in Charles River Laboratories International, Inc. (CRL) was 8,178 shares, as reported at the end of Q1 2026.